about
Killing cancer cells by targeted drug-carrying phage nanomedicinesSynthesis of site-specific antibody-drug conjugates using unnatural amino acidsMechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancerModulation of APC Function and Anti-Tumor Immunity by Anti-Cancer DrugsAntibody-drug conjugates as novel anti-cancer chemotherapeuticsAntibody Drug Conjugates: Preclinical ConsiderationsProanthocyanidin from Blueberry Leaves Suppresses Expression of Subgenomic Hepatitis C Virus RNAEvolution and function of the ADP ribosyl cyclase/CD38 gene family in physiology and pathologyAntibody drug conjugates: design and selection of linker, payload and conjugation chemistryCaveolin-1 Dependent Endocytosis Enhances the Chemosensitivity of HER-2 Positive Breast Cancer Cells to Trastuzumab Emtansine (T-DM1)Development and Evaluation of a Fluorescent Antibody-Drug Conjugate for Molecular Imaging and Targeted Therapy of Pancreatic CancerThe success story of trastuzumab emtansine, a targeted therapy in HER2-positive breast cancer.Trastuzumab emtansine: mechanisms of action and drug resistanceTumor vasculature targeted photodynamic therapy for enhanced delivery of nanoparticles.Treating breast cancer in the 21st century: emerging biological therapiesComputational Construction of Antibody-Drug Conjugates Using Surface Lysines as the Antibody Conjugation Site and a Non-cleavable LinkerMethods to Make Homogenous Antibody Drug Conjugates.Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo.Pharmacodynamics, tissue distribution, toxicity studies and antitumor efficacy of the vascular targeting fusion toxin VEGF121/rGelHetero-modification of TRAIL trimer for improved drug delivery and in vivo antitumor activities.A Conjugate Based on Anti-HER2 Diaffibody and Auristatin E Targets HER2-Positive Cancer Cells.Photonanomedicine: a convergence of photodynamic therapy and nanotechnology.The role of carbonic anhydrase IX as a molecular marker for transitional cell carcinoma of the bladder.Determination of Cellular Processing Rates for a Trastuzumab-Maytansinoid Antibody-Drug Conjugate (ADC) Highlights Key Parameters for ADC Design.Challenges in developing bioanalytical assays for characterization of antibody-drug conjugates.Optimising the delivery of tubulin targeting agents through antibody conjugation.ADME of antibody-maytansinoid conjugatesThe antibody-drug conjugate: an enabling modality for natural product-based cancer therapeutics.Trends in cancer-targeted antibody-drug conjugates.Biomedical applications of trastuzumab: as a therapeutic agent and a targeting ligand.Antibody Drug Conjugates: Application of Quantitative Pharmacology in Modality Design and Target Selection.Antibodies as stratagems against cancer.Application of a PK-PD Modeling and Simulation-Based Strategy for Clinical Translation of Antibody-Drug Conjugates: a Case Study with Trastuzumab Emtansine (T-DM1).Strategies and challenges for the next generation of antibody-drug conjugates.Maytansinoid-antibody conjugates induce mitotic arrest by suppressing microtubule dynamic instability.Antibody Drug Conjugate bioinformatics: drug delivery through the letterboxImmunogenicity of antibody drug conjugates: bioanalytical methods and monitoring strategy for a novel therapeutic modality.A CXCR4-targeted site-specific antibody-drug conjugate.Targeted Delivery of an Anti-inflammatory PDE4 Inhibitor to Immune Cells via an Antibody-drug Conjugate.Antibody-Drug Conjugates: Pharmacokinetic/Pharmacodynamic Modeling, Preclinical Characterization, Clinical Studies, and Lessons Learned.
P2860
Q21256651-EDF82B70-62B1-4E0E-AC31-BA346473C749Q24624489-921C9D06-E7F5-4F0C-B2AC-3136CBA5B4EDQ26772969-6D13E6D9-6861-4341-9033-8F156B869B66Q26781522-6A266EEE-60C9-499A-A7E6-12DE12B66612Q26800175-36387342-48CC-43DB-9990-80EA3461E3AEQ27022321-53287053-8A52-4259-A9FB-CB2EA492B7BFQ27489836-AD62A907-BE11-4A20-BA27-CD2EDFE176A4Q28287124-6869543C-D9FF-4E60-9BA4-F4B3964DD9BAQ28544658-7B30A3CE-F6A1-4C62-8296-94EC752AD169Q28546477-517DD15D-2552-4934-A29B-EB1BC1E66E44Q28552050-09F32A48-8A25-4D17-AD3F-3AA4DDD48545Q33409083-EE6B56D4-1544-4355-9037-51A46CD78698Q33759627-821B6376-AC28-446D-AD0B-A713059ADF02Q33824812-CA3092C9-F550-4CFA-964C-EBB41843F567Q34326536-6D86C8D2-8879-4DBC-95C2-03F77DF688A9Q34663010-5DB85EEB-155E-46B7-9896-DE9A2D6C8414Q35523479-BC48EE3F-BDC7-48F5-B911-F77D2F5812A9Q35559041-B284E6BB-3978-4A9D-9E45-CA3C4697450FQ35580988-16BA9453-C1C1-420A-8ACC-A2AECEA92B1FQ36134152-CC049FED-9010-432C-82FB-1079F9FDB5D9Q36285117-9D73E3BF-BDAA-4A3D-A17E-D5A71F38B4E7Q37115994-214CC980-EFB1-4DA3-ACE6-C3EA77997772Q37145181-2FF8930C-ED10-4C37-B03E-D40A7BE327FAQ37600390-E2483A63-643E-4ABC-B8AC-BF453B1074F5Q37854644-9B198CDF-18D5-480B-BFA3-85137FF280A8Q38024991-8909B4BA-A73E-43F0-933C-C65AA0F2FEC8Q38033114-1B7E85B4-4FE8-4CDF-8E4E-F426BF627FD1Q38092648-01EBE409-3E81-4C02-A079-52AEE81DB1A2Q38162127-651222E2-F698-4C8C-80A2-6DFC635921E0Q38408138-A11912C1-A435-4646-8CF1-94CB5E5ABE78Q38453769-0F8133E2-C9E2-4344-B5E8-60DC6D777F94Q38688747-6A3D1A7C-6F81-4007-B4BD-ADFA8DB56926Q38856969-A5A5C8B0-BF8A-4DC8-B40B-09627D89A606Q39182945-B6DFBA3F-6FD4-40E9-BFB4-B4804E744D81Q39645683-AC839894-62FA-4F46-8A64-16AD3D378621Q41858314-F5FAA31D-4B75-4916-834F-1D4BBCD9618FQ43096291-D3543304-43D0-4A66-98EF-FB1177A75914Q43150353-35300F47-1B3E-45F3-BDF7-20A94DD794DFQ46120241-F5E43126-8082-4BCA-ABF9-2739BA0BF414Q46209550-571D784E-2F40-47FE-9857-63AD98E805CB
P2860
description
2007 nî lūn-bûn
@nan
2007 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
name
Cell killing by antibody-drug conjugates.
@ast
Cell killing by antibody-drug conjugates.
@en
Cell killing by antibody-drug conjugates.
@nl
type
label
Cell killing by antibody-drug conjugates.
@ast
Cell killing by antibody-drug conjugates.
@en
Cell killing by antibody-drug conjugates.
@nl
prefLabel
Cell killing by antibody-drug conjugates.
@ast
Cell killing by antibody-drug conjugates.
@en
Cell killing by antibody-drug conjugates.
@nl
P1433
P1476
Cell killing by antibody-drug conjugates.
@en
P2093
Victor S Goldmacher
Yelena V Kovtun
P304
P356
10.1016/J.CANLET.2007.04.010
P407
P577
2007-06-05T00:00:00Z